adAPT is a randomised controlled clinical trial designed to test the Accelerator Hypothesis.

Visit the adAPT website

Autoimmune Diabetes Accelerator Prevention Trial (adAPT)

The autoimmune diabetes Accelerator Prevention Trial (adAPT) is a randomised controlled clinical trial designed to test the Accelerator Hypothesis, a new and alternative explanation for type 1 diabetes. A successful outcome would offer a means of preventing diabetes in children and, importantly, demonstrate the mechanism responsible.

The aim of adAPT is to test the hypothesis that childhood diabetes can be prevented in those at risk by reducing demand on the beta cells which make insulin. Rather than use immunotherapy to control the immune system, it aims to show that type 1 diabetes, like type 2 diabetes, can be prevented by reducing insulin requirement.

The trial is led by the University of Exeter, funded by the Juvenile Diabetes Research Foundation (JDRF) and conducted in Scotland by the Tayside Clinical Trials Unit of the University of Dundee.

For further information on the adAPT trial please contact Professor Terry Wilkin or visit the adAPT website.